摘要2020年11月，美国重症肌无力基金会（Myasthenia Gravis Foundation of America，MGFA）在线发布了《重症肌无力管理国际共识指南：2020更新版》，在保留7个重症肌无力治疗主题的基础上，新增2个治疗主题（眼肌型重症肌无力和免疫检查点抑制剂相关性重症肌无力），同时修订了胸腺切除主题的内容，并且在重症肌无力与免疫抑制治疗主题中新增利妥昔单抗、依库珠单抗和甲氨蝶呤治疗。本文对2020更新版的修订及新增内容进行概述，以供同道参考。
Abstract：In November 2020, Myasthenia Gravis Foundation of America (MGFA) released International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update online. In addition to retaining seven topics for myasthenia gravis, two new topics (ocular myasthenia gravis and immune checkpoint inhibitor-associated myasthenia gravis) were included in this guideline. Furthermore, the previous recommendations for thymectomy were updated, and the new recommendations were developed for the use of rituximab, eculizumab, and methotrexate in the topic of myasthenia gravis and immunosuppression therapy. This paper summarizes the updated recommendations and new contents in this guideline.
李建萍. 《重症肌无力管理国际共识指南：2020 更新版》解读[J]. 神经病学与神经康复学杂志, 2021, 17(1): 32-38.
LI Jianping. Comments on International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Journal of Neurology and Neurorehabilitation, 2021, 17(1): 32-38.
2021, Vol. 17 
